Bio-Rad (BIO) stock price, revenue, and financials

Bio-Rad market cap is $21.6 b, and annual revenue was $2.55 b in FY 2020

$21.6 B

BIO Mkt cap, 15-Oct-2021

$726.8 M

Bio-Rad Revenue Q1, 2021
Bio-Rad Gross profit (Q1, 2021)400.6 M
Bio-Rad Gross profit margin (Q1, 2021), %55.1%
Bio-Rad Net income (Q1, 2021)977.4 M
Bio-Rad EBIT (Q1, 2021)100.9 M
Bio-Rad Cash, 31-Mar-2021673.5 M
Bio-Rad EV21.1 B
Get notified regarding key financial metrics and revenue changes at Bio-RadLearn more
Banner background

Bio-Rad Revenue

Bio-Rad revenue was $2.55 b in FY, 2020

Embed Graph

Bio-Rad Revenue Breakdown

Embed Graph

Bio-Rad revenue breakdown by business segment: 61.7% from Clinical Diagnostics, 37.6% from Life Science and 0.7% from Other

Bio-Rad revenue breakdown by geographic segment: 34.6% from Europe, 21.6% from Pacific Rim, 37.7% from United States and 6.0% from Other (primarily Canada and Latin America)

Bio-Rad Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

2.0b2.1b2.2b2.3b2.3b2.5b

Revenue growth, %

(7%)2%4%6%

Cost of goods sold

897.8m930.1m972.8m1.1b1.1b1.1b

Gross profit

1.1b1.1b1.2b1.2b1.3b1.4b

Gross profit Margin, %

56%55%55%53%54%56%

R&D expense

193.0m205.9m250.3m199.2m202.7m226.6m

General and administrative expense

762.0m816.7m808.9m834.8m824.6m800.3m

Operating expense total

955.0m1.1b1.1b1.3b1.0b1.0b

EBIT

166.7m53.2m116.7m(103.3m)229.7m411.0m

EBIT margin, %

8%3%5%(5%)10%16%

Interest expense

21.7m21.9m21.9m24.0m23.4m21.9m

Pre tax profit

145.8m41.6m97.8m512.7m2.3b4.9b

Income tax expense

32.8m13.4m24.4m147.0m502.4m1.1b

Net Income

113.1m28.1m122.2m365.6m1.7b3.8b

Bio-Rad Balance Sheet

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

403.6m418.7m417.9m291.7m321.6m328.9m407.3m403.0m434.5m455.9m580.7m561.1m603.6m607.6m840.3m673.5m

Accounts Receivable

381.1m366.3m367.7m373.4m392.8m419.7m430.4m404.1m381.5m391.7m377.9m356.0m380.5m360.9m402.2m408.1m

Prepaid Expenses

125.7m141.2m164.0m122.4m109.6m94.8m91.8m111.3m110.3m

Inventories

533.3m541.5m556.4m559.8m580.6m601.6m612.2m591.4m601.1m590.4m589.9m588.0m557.0m628.4m640.2m605.2m

Current Assets

1.8b1.8b1.9b1.7b1.8b1.9b2.0b2.0b2.0b2.0b2.1b2.0b2.1b2.1b2.3b2.2b

PP&E

449.2m457.7m474.7m505.1m503.3m500.7m499.7m490.2m484.3m503.0m499.2m495.9m486.2m

Goodwill

509.6m230.7m506.6m516.2m530.3m520.7m510.4m500.0m501.9m230.5m235.4m264.1m264.1m

Total Assets

3.8b3.9b4.0b4.0b4.1b4.2b6.2b6.4b6.7b6.9b7.6b7.2b8.7b10.1b12.0b13.9b

Accounts Payable

118.2m130.9m133.0m138.5m

Short-term debt

296.0k294.0k297.0k466.0k505.0k452.0k369.0k1.7m1.8m36.2m35.7m35.5m34.4m34.4m39.2m

Current Liabilities

400.9m410.4m442.7m407.5m455.1m466.5m456.2m442.4m453.2m444.3m446.0m434.0m869.3m926.9m986.7m609.9m

Long-term debt

434.0m434.1m434.1m434.3m434.4m434.5m434.7m438.8m438.8m437.6m625.4m630.4m12.2m185.3m184.4m168.3m

Total Debt

434.3m434.4m434.4m434.8m434.9m434.9m435.0m440.5m440.6m473.8m661.1m665.9m46.6m185.3m218.8m207.6m

Total Liabilities

1.2b1.3b1.3b1.2b1.3b1.3b1.7b1.7b1.8b2.0b2.2b2.0b2.4b2.7b3.2b3.3b

Common Stock

3.0k3.0k3.0k3.0k3.0k3.0k3.0k3.0k3.0k3.0k3.0k3.0k

Additional Paid-in Capital

308.9m316.8m324.6m342.6m347.7m350.7m371.0m376.6m382.4m402.8m410.6m396.4m423.7m429.5m412.3m445.1m

Retained Earnings

1.8b1.8b1.9b1.8b1.9b1.9b4.0b4.3b4.6b4.6b5.2b4.9b6.2b7.1b8.4b10.2b

Total Equity

2.5b2.6b2.7b2.7b2.8b2.8b4.5b4.6b4.9b4.9b5.5b5.1b6.3b7.4b8.8b10.6b

Debt to Equity Ratio

0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x

Financial Leverage

1.5 x1.5 x1.5 x1.5 x1.5 x1.5 x1.4 x1.4 x1.4 x1.4 x1.4 x1.4 x1.4 x1.4 x1.4 x1.3 x

Bio-Rad Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

113.1m28.1m122.2m365.6m

Depreciation and Amortization

131.8m142.9m148.7m138.1m

Accounts Receivable

(39.0m)12.5m(64.1m)59.7m1.6m

Inventories

(54.2m)(5.7m)(47.7m)(12.9m)24.2m(52.1m)

Accounts Payable

28.6m30.1m7.8m(45.6m)

Cash From Operating Activities

186.2m216.4m103.9m285.5m457.9m575.3m

Purchases of PP&E

(98.5m)(98.9m)

Capital Expenditures

(112.0m)(141.4m)(111.3m)(129.8m)

Cash From Investing Activities

(166.9m)(213.9m)(175.6m)(187.0m)(208.9m)(60.2m)

Short-term Borrowings

37.0k(36.0k)

Long-term Borrowings

(282.0k)(303.0k)(316.0k)(3.0m)(643.0k)(426.9m)

Cash From Financing Activities

8.6m9.0m341.0k(48.7m)(22.8m)(523.0m)

Net Change in Cash

44.3m(1.3m)(72.4m)49.2m228.5m4.5m

Interest Paid

20.8m21.3m21.1m22.7m

Income Taxes Paid

31.7m38.4m52.1m62.4m

Free Cash Flow

74.2m75.0m(7.4m)155.7m

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

12.3m30.3m48.7m12.4m17.4m44.8m656.8m924.8m1.2b865.2m1.5b1.2b

Depreciation and Amortization

34.1m71.7m110.2m33.7m70.7m106.1m34.3m68.7m103.6m32.9m66.1m99.8m

Accounts Receivable

20.0m32.1m32.7m6.8m(1.8m)(22.4m)40.2m52.5m72.2m(2.0m)14.6m30.4m2.2m24.7m(9.6m)1.3m

Inventories

(34.4m)(51.0m)(67.9m)(26.9m)(37.9m)(56.2m)(16.9m)(11.7m)(26.3m)(11.6m)(8.0m)(14.5m)(13.7m)(79.8m)(83.5m)5.8m

Accounts Payable

(47.7m)(32.6m)(4.6m)(61.2m)(24.2m)(19.1m)(47.4m)(43.7m)(43.1m)20.6m(23.0m)(24.6m)

Cash From Operating Activities

(7.4m)69.7m121.3m(56.2m)6.2m34.5m40.3m118.2m180.5m42.9m198.3m298.1m62.8m154.9m290.6m113.6m

Purchases of PP&E

(21.6m)(39.7m)(59.7m)(19.5m)

Capital Expenditures

(25.3m)(56.9m)(96.3m)(39.3m)(65.0m)(85.3m)(27.2m)(53.9m)(76.0m)(23.6m)(45.8m)(76.9m)

Cash From Investing Activities

(50.9m)(110.3m)(163.8m)(110.4m)(147.7m)(162.5m)(18.8m)(102.7m)(132.2m)(22.7m)(37.8m)(147.7m)(12.4m)(101.0m)(10.1m)(48.3m)

Short-term Borrowings

(36.0k)(36.0k)(36.0k)

Long-term Borrowings

(77.0k)(156.0k)(231.0k)(76.0k)(149.0k)(220.0k)(87.0k)(1.5m)(1.6m)(237.0k)(359.0k)(487.0k)(1.5m)(1.6m)(1.8m)(1.4m)

Cash From Financing Activities

258.0k3.3m6.2m673.0k(395.0k)(3.2m)2.5m499.0k(1.7m)2.2m(13.5m)(18.0m)(98.6m)(101.6m)(101.2m)(47.3m)

Net Change in Cash

(53.9m)(38.9m)(39.6m)(164.6m)(134.7m)(127.4m)22.7m19.1m50.6m24.4m149.2m129.2m(54.2m)(50.5m)182.5m10.6m

Interest Paid

187.0k10.9m11.2m10.3m10.6m378.0k11.3m11.7m459.0k11.1m11.4m

Income Taxes Paid

11.1m37.4m8.8m19.1m39.8m3.2m47.6m57.8m4.6m24.0m42.6m

Free Cash Flow

(32.7m)12.8m25.0m(95.6m)(58.8m)(50.7m)13.2m64.3m104.5m19.3m152.5m221.2m

Bio-Rad Ratios

USDFY, 2015

Revenue/Employee

259.9k

Debt/Equity

0.2 x

Debt/Assets

0.1 x

Financial Leverage

1.5 x

Bio-Rad Operating Metrics

FY, 2015FY, 2016FY, 2017FY, 2018Apr, 2020

Products

8 k8 k9 k9 k

Products (Life Science)

5 k5 k6 k6 k

Products (Clinical Diagnostics)

3 k3 k3 k3 k

Clinical Diagnostic Tests Covered

300300300300

Customers (Healthcare Providers)

15 k

Patents Issued

2 k

Bio-Rad Employee Rating

3.5883 votes
Culture & Values
3.3
Work/Life Balance
3.6
Senior Management
3
Salary & Benefits
3.5
Career Opportunities
3
Source